Recurrent genital herpes quality of life measure

The Recurrent Genital Herpes Quality of Life (RGHQoL) measure is a patient-reported outcome measure which determines the impact that recurrent genital herpes has on a patient’s quality of life. It is a 20 item questionnaire[1] with items such as “Herpes makes it difficult for me to plan ahead” and “I worry that sex will trigger an outbreak.”.[2] Lower scores on the RGHQoL indicate a higher negative impact on quality of life.[3]

Background

The RGHQoL was published in 1998 by Galen Research and was funded by Glaxo Wellcome Research & Development. The content of the measure was taken from qualitative interviews conducted with patients with recurrent genital herpes. The initial interviews were conducted in the UK and then an international panel was assembled in order to translate and validate the measure for the UK, USA, Italy, France, Germany and Denmark. Items were translated and then field tested with up to 20 RGH patients in each country. The test-retest correlations for each language version was found to be in excess of 0.85, meaning every version had good reliability.[4]

International use

The RGHQoL has been used in numerous clinical studies worldwide as a tool for assessing new treatments and measuring quality of life. It has been utilized in studies investigating suppressive antiviral therapy,[5] famciclovir[6] and quality of life.[7]

References

  1. ↑ Doward, LC; McKenna, SP; Kohlmann, T; Niero, M; Patrick, D; Spencer, B; Thorsen, H (February 1998). "The international development of the RGHQoL: a quality of life measure for recurrent genital herpes.". Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 7 (2): 143–53. doi:10.1023/A:1008857426633. PMID 9523496.
  2. ↑ "RGHQoL" (PDF). Galen-Research.com. Galen Research. Retrieved 2 December 2013.
  3. ↑ Patel, R; Boselli, F; Cairo, I; Barnett, G; Price, M; Wulf, HC (October 2001). "Patients' perspectives on the burden of recurrent genital herpes.". International journal of STD & AIDS. 12 (10): 640–5. doi:10.1258/0956462011923859. PMID 11564330.
  4. ↑ Doward, LC; McKenna, SP; Kohlmann, T; Niero, M; Patrick, D; Spencer, B; Thorsen, H (February 1998). "The international development of the RGHQoL: a quality of life measure for recurrent genital herpes.". Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 7 (2): 143–53. doi:10.1023/A:1008857426633. PMID 9523496.
  5. ↑ Patel, R; Tyring, S; Strand, A; Price, MJ; Grant, DM (December 1999). "Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection.". Sexually transmitted infections. 75 (6): 398–402. doi:10.1136/sti.75.6.398. PMC 1758256Freely accessible. PMID 10754944.
  6. ↑ Bartlett BL, Tyring SK, Fife K, Gnann JW, Hadala JT, Kianifard F, Berber E (October 2008). "Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial.". Journal of Clinical Virology. 43 (2): 190–5. doi:10.1016/j.jcv.2008.06.004. PMID 18621575.
  7. ↑ Patel, R; Boselli, F; Cairo, I; Barnett, G; Price, M; Wulf, HC (October 2001). "Patients' perspectives on the burden of recurrent genital herpes.". International journal of STD & AIDS. 12 (10): 640–5. doi:10.1258/0956462011923859. PMID 11564330.
This article is issued from Wikipedia - version of the 7/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.